Julio Castro

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment

Melanie Mediavilla-Varela, Julio Castro, Alberto Chiappori et al. · Neoplasia · 2017 · 88 citations · Full text

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto Chiappori, Ben Creelan, Tawee Tanvetyanon et al. · Clinical Cancer Research · 2022 · 65 citations · Full text

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 55 citations

Antifibrotic Therapy, Fortis-m Trial, Medicine +9

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

Alberto Chiappori, Charles C. Williams, Ben Creelan et al. · Journal of Clinical Oncology · 2018 · 45 citations

Immunology, Immunoediting, Pharmacotherapy +22

Prenatal hypertrophic cardiomyopathy and pericardial effusion in carbohydrate‐deficient glycoprotein syndrome

M. T. García Silva, Julio Castro, Helena Stibler et al. · Journal of Inherited Metabolic Disease · 1996 · 26 citations